HomeThemesTypesDBAbout
Showing: ◈ drug certification×
Leading pharmaceutical research firm finds some drug firms will withdraw up to 90 per cent of their products from Northern Ireland as protocol hits exports.
Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions.
The UK’s MHRA may have to lay off about 300 of its 1,200 employees, thanks to a decline in income due to reduced medical product submissions following Brexit, spurring anger among unions across the island.
Dr Philippa Whitford, MP and eminent breast cancer surgeon, shares her concerns for the future of our NHS following Brexit. Recorded in front of a live audience at Arran High School Theatre on Friday 13th September 2019.
And it will cost more here because of the UK pulling out of the European Medicines Agency on 30 December.
Everyone is fishing in the same pond. Stocks built up in readiness for Brexit are having to be replenished. If another pandemic strikes, we’ll hardly be in the best position to get through it.
With the NHS under such exceptional pressure during the coronavirus crisis, it’s easy to overlook the fact that the UK’s Brexit transition period ends on December 31. Mark Dayan takes a closer look at how these two challenges for the health service might collide, and says there is a case to err on the side of caution.
Ministers will relax rules around clinical trials and streamline the approval of new medicines in a bid to maintain Britain’s competitiveness following Brexit.
Brexit could have major implications for health and social care in England. Here we look at some of the latest developments that could have an impact.
US, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit, the CEO of French pharma Ipsen has said in an interview.
David Meek, the CEO of Ipsen, warns Britain leaving the European Union has seen the country fall down the list of priorities.